Balance Sheet

Cash Flow Statement

Amortization Amortization Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Legend Biotech (LEGN) Amortization (2020 - 2025)

Legend Biotech filings provide 6 years of Amortization readings, the most recent being -$20.8 million for Q3 2025.

On a quarterly basis, Amortization rose 57.67% to -$20.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$99.1 million, a 62.05% increase, with the full-year FY2022 number at -$402.5 million, down 11.37% from a year prior.
Amortization hit -$20.8 million in Q3 2025 for Legend Biotech, down from $3.5 million in the prior quarter.
In the past five years, Amortization ranged from a high of $3.5 million in Q2 2025 to a low of -$402.5 million in Q4 2022.
Median Amortization over the past 5 years was -$73.1 million (2021), compared with a mean of -$93.7 million.
Biggest five-year swings in Amortization: plummeted 2529.46% in 2024 and later surged 137.88% in 2025.
Legend Biotech's Amortization stood at -$361.4 million in 2021, then fell by 11.37% to -$402.5 million in 2022, then soared by 100.5% to $2.0 million in 2023, then plummeted by 2529.46% to -$49.1 million in 2024, then soared by 57.67% to -$20.8 million in 2025.
The last three reported values for Amortization were -$20.8 million (Q3 2025), $3.5 million (Q2 2025), and -$32.7 million (Q1 2025) per Business Quant data.